Liquid Biopsy Metabolic Panel - BioMark Diagnostic

Validating a new high-powered liquid biopsy metabolic panel assay for early diagnosis of Lung Cancer.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

Metabolic Panel Assays

BioMark Liquid Biopsy Metabolic Panel Assays

BioMark has invested in and developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early stage diagnosis of lung cancer.
 
The liquid biopsy metabolic panel has demonstrated superior clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
 
This is a major breakthrough in Lung Cancer diagnostics.
 
The discovery positions BioMark for high risk lung cancer screening. This market currently uses low dose CT scans (LDCT). Machine learning is being used by BioMark in the analysis of the assay.

Cancer Research

Liquid Biopsy Metabolic Panels Being Developed for Other Cancers

  • Glioblastoma (GBM)
  • Breast Cancer
  • Head & Neck Cancer

Application:

  • Screening for high risk group
  • Precision medicine
  • Assess high risk relapse population cohort
  • Assess malignancy

Clinical Trials:

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open

 

Spermidine/spermine N-acetyltransferase 1 (SSAT1) Gene Expression and Identification of High-Performance Metabolites in Human Cancer (Amended)

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute

Status: Open

Glioblastoma (GBM)

  • CancerCare Manitoba ethics approval obtained for the protocol
  • Patients to be recruited newly diagnosed and treated
  • Utilize both SSAT1 and new panels
  • Expand clinical trial sites in N. America

Breast Cancer

  • Identified and validated several putative markers
  • Expanding trial samples
  • Incorporate other clinical and imaging data

Head / Neck Cancer

  • In discussion with a major European centre to develop a comprehensive Omics panel of markers for high relapse cancer cohort
  • Modify protocol and potentially extend trial to additional North American sites after Health Canada and ethics approvals are granted.

Identification of Circulating markers to customize the follow-up of head and neck cancer patients for early identification of recurrences/second tumors

Principal Investigators: Dr. Paolo Rossi and Dr. Cristina Gurizzan, University of Brescia, Italy
Status: Open.

Patients have been recruited for the study at University of Brescia in Italy. The study is being led by Prof. Paolo Bossi and Dr. Cristina Gurizzan both from the Oncology Department. The collaboration is on the development and validation of a comprehensive Omics panel of markers for high relapse head and neck cancer cohort.

BioMark will modify the protocol and potentially extend this trial to additional North American sites after Health Canada and ethics approvals are granted.

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

early stage cancer detection - BioMark Diagnostics we believe cancer can be cured
early stage cancer detection - BioMark Diagnostics we believe cancer can be cured

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.